Beam Therapeutics (BEAM) Retained Earnings (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Retained Earnings data on file, last reported at -$1.7 billion in Q1 2026.

• On a quarterly basis, Retained Earnings fell 1.44% year-over-year to -$1.7 billion in Q1 2026; TTM through Mar 2026 was -$1.7 billion, a 1.44% decrease from a year earlier, with the FY2025 full-year figure at $1.1 million, down 99.95% from the prior year.
• Retained Earnings for Q1 2026 stood at -$1.7 billion, down from $1.1 million in the prior quarter.
• Over the last five years, Retained Earnings for BEAM reached as high as $2.9 billion in Q3 2025 and fell as low as -$1.7 billion in Q1 2026.
• Historically, Retained Earnings has averaged -$67.5 million across 5 years, with a median of -$1.0 billion in 2022.
• Across the five-year window, Retained Earnings plunged 2114624.0% in 2022 and surged 325.36% in 2023, its largest moves.
• Year by year, Retained Earnings stood at -$1.1 billion in 2022, then retreated by 12.53% to -$1.2 billion in 2023, then surged by 293.18% to $2.3 billion in 2024, then plunged by 99.95% to $1.1 million in 2025, then slumped by 153115.3% to -$1.7 billion in 2026.
• Per Business Quant data, the three most recent Retained Earnings figures were -$1.7 billion in Q1 2026, $1.1 million in Q4 2025, and $2.9 billion in Q3 2025.